SCHEMBL3075166

SCHEMBL3075166

O=C(c1nc2c(C(F)(F)F)cc(Cl)cn2c1Cl)N1CCC(N2CCCC2=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
F10 P00742 3/20 0.39
P2RX7 Q99572 1/20 0.38
KDM5A P29375 1/20 0.37
TACR2 P21452 1/20 0.37
TACR1 P25103 1/20 0.37
TACR3 P29371 1/20 0.37
SYK P43405 2/20 0.36
ENPP2 Q13822 2/20 0.36
RBP4 P02753 3/20 0.35
VNN1 O95497 1/20 0.35
PROKR1 Q8TCW9 3/20 0.35
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075890 0.91 IRAK4 (0.38) IRAK4F10P2RX7KDM5ATACR2
SCHEMBL3064195 0.90 IRAK4 (0.38) IRAK4F10P2RX7KDM5ATACR2
SCHEMBL1583246 0.86 P2RX7 (0.54) KMT2AIRAK4P2RX7RBP4PROKR1
SCHEMBL3063204 0.85 P2RX7 (0.43) IRAK4F10P2RX7KDM5ATACR2
SCHEMBL3058447 0.85 IRAK4 (0.36) IRAK4F10P2RX7KDM5ATACR2
SCHEMBL3071123 0.85 PIK3CD (0.36) IRAK4F10KDM5ASYKENPP2
SCHEMBL3061546 0.84 F10 (0.40) KMT2AF10ENPP2RBP4VNN1
SCHEMBL1583119 0.83 P2RX7 (0.46) KMT2AIRAK4P2RX7RBP4PROKR1
SCHEMBL3785019 0.82 ENPP2 (0.37) IRAK4F10P2RX7TACR2TACR1
SCHEMBL3063288 0.79 KDM5A (0.32) IRAK4KDM5AVNN1PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US claimed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO claimed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents ZC3HAV1, MAVS, EIF2AK2 KMT2A 4584/4885IRAK4 2506/4885F10 2944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.